Vertex Pharmaceutic (VRTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 5,084,800 | 4,569,600 | 10,369,100 | 10,504,000 | 6,795,000 |
| Marketable Securities | 1,523,300 | 1,546,300 | 849,200 | 274,500 | 729,900 |
| Receivables | 2,052,800 | 1,609,400 | 1,563,400 | 1,442,200 | 1,136,800 |
| Inventories | 1,686,800 | 1,205,400 | 738,800 | 460,600 | 353,100 |
| TOTAL | $11,201,000 | $9,596,400 | $14,144,200 | $13,234,800 | $9,560,600 |
| Non-Current Assets | |||||
| PPE Net | 1,520,300 | 1,227,800 | 1,159,300 | 1,108,400 | 1,094,100 |
| Investments And Advances | 5,712,300 | 5,107,900 | 2,497,800 | 112,200 | 0 |
| Intangibles | 1,512,200 | 1,913,900 | 1,927,900 | 1,691,600 | 1,402,200 |
| Other Non-Current Assets | 5,697,200 | 4,687,200 | 3,001,000 | 2,003,900 | 1,375,600 |
| TOTAL | $14,442,000 | $12,936,800 | $8,586,000 | $4,916,100 | $3,871,900 |
| Total Assets | $25,643,000 | $22,533,200 | $22,730,200 | $18,150,900 | $13,432,500 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 461,700 | 413,000 | 364,900 | 303,900 | 195,000 |
| Accrued Expenses | 2,971,200 | 2,788,600 | 2,655,300 | 2,126,700 | 1,678,600 |
| Other current liabilities | 428,300 | 363,000 | 527,200 | 311,500 | 268,400 |
| TOTAL | $3,861,200 | $3,564,600 | $3,547,400 | $2,742,100 | $2,142,000 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 3,116,000 | 2,559,000 | 1,226,300 | 1,065,300 | 680,700 |
| TOTAL | $3,116,000 | $2,559,000 | $1,602,400 | $1,496,100 | $1,190,500 |
| Total Liabilities | $6,977,200 | $6,123,600 | $5,149,800 | $4,238,200 | $3,332,500 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | N/A | 256,790 | 258,308 | 257,091 | 254,577 |
| Common Shares | 2,500 | 2,600 | 2,600 | 2,600 | 2,500 |
| Retained earnings | 13,560,000 | 9,606,800 | 10,142,400 | 6,522,800 | 3,200,800 |
| Other shareholders' equity | -15,900 | 127,800 | -14,300 | 800 | 15,900 |
| TOTAL | $18,665,800 | $16,409,600 | $17,580,400 | $13,912,700 | $10,100,000 |
| Total Liabilities And Equity | $25,643,000 | $22,533,200 | $22,730,200 | $18,150,900 | $13,432,500 |